Esaxerenone as an Add-On Therapy to RAS Inhibitors: Clinical Evidence and Therapeutic Insights

Abstract

The utilization of esaxerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), as an adjunct to renin-angiotensin system (RAS) inhibitors represents a significant advancement in the management of hypertension and related cardiovascular and renal conditions. This review synthesizes current evidence on the clinical efficacy, safety, and mechanistic rationale for combining esaxerenone with RAS inhibitors, with a focus on optimizing outcomes in patients with resistant hypertension, diabetic nephropathy, and chronic kidney disease. We discuss epidemiological trends, pathophysiological underpinnings, key risk factors, clinical features, diagnostic considerations, and guideline-based management, highlighting the implications of recent clinical trials and emerging therapeutic strategies.

Introduction

Hypertension and its associated comorbidities, such as chronic kidney disease (CKD) and heart failure, remain leading global health concerns. While RAS inhibitors, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are foundational in the management of these diseases, a substantial proportion of patients exhibit suboptimal response or persistent proteinuria despite optimized RAS blockade. The addition of mineralocorticoid receptor antagonists (MRAs), particularly esaxerenone, offers a mechanistically distinct and evidence-based approach to addressing aldosterone-mediated target organ damage, with favorable safety and efficacy profiles emerging from recent trials.

Epidemiology / Disease Burden

The global prevalence of hypertension exceeds 1.2 billion adults, with resistant hypertension—defined as uncontrolled blood pressure despite the use of at least three antihypertensives, including a diuretic—affecting up to 15% of this population. The burden of diabetic nephropathy and CKD is likewise substantial, contributing to increased cardiovascular morbidity and mortality. Despite widespread use of RAS inhibitors, residual risk for progression of kidney disease and cardiovascular events persists, underscoring the need for adjunctive therapies such as esaxerenone.

Pathophysiology

Aldosterone, acting via the mineralocorticoid receptor (MR), promotes sodium retention, potassium excretion, vascular inflammation, fibrosis, and endothelial dysfunction. In the context of RAS inhibition, "aldosterone breakthrough"—the phenomenon in which plasma aldosterone levels rise despite effective RAS blockade—can contribute to ongoing target organ injury. Esaxerenone, as a highly selective non-steroidal MRA, competitively antagonizes MR activation, thereby mitigating aldosterone-mediated pathophysiological processes. Its unique pharmacological profile results in robust antihypertensive and renoprotective effects, with lower risks of hyperkalemia and off-target adverse effects compared to traditional steroidal MRAs.

Risk Factors

Key risk factors for suboptimal response to RAS inhibitors and progression of cardiorenal disease include poorly controlled blood pressure, diabetes mellitus, advanced age, obesity, high dietary sodium intake, and genetic predisposition to aldosterone excess. Additionally, African ancestry, chronic inflammation, and pre-existing renal impairment further contribute to the risk of aldosterone breakthrough and resistant hypertension, necessitating individualized therapeutic approaches.

Clinical Features

Patients who may benefit from esaxerenone add-on therapy typically present with persistent hypertension, microalbuminuria or overt proteinuria, and progressive decline in glomerular filtration rate (GFR) despite maximally tolerated RAS inhibition. Clinical manifestations may include signs of fluid retention, left ventricular hypertrophy, and evidence of end-organ damage on laboratory or imaging assessments. Careful monitoring for hyperkalemia, renal function deterioration, and electrolyte disturbances is essential in this population.

Diagnosis

Diagnosis of resistant hypertension and RAS inhibitor-resistant proteinuria involves repeated blood pressure assessments, comprehensive medication reconciliation, and exclusion of secondary causes such as primary aldosteronism or renovascular hypertension. Laboratory evaluation should encompass serum creatinine, estimated GFR, serum potassium, urinary albumin-to-creatinine ratio (UACR), and, when indicated, plasma aldosterone and renin levels. Ambulatory blood pressure monitoring and assessment of adherence are critical to confirm true resistance.

Treatment & Management

The cornerstone of management includes lifestyle modification, optimization of antihypertensive regimens, and maximization of RAS blockade. When blood pressure or proteinuria remains uncontrolled, the addition of esaxerenone offers a rational and effective strategy. Esaxerenone is initiated at a low dose, titrated according to blood pressure response, proteinuria reduction, and tolerability. Ongoing monitoring of serum potassium and renal function is paramount, particularly in patients with advanced CKD or concomitant use of other potassium-sparing agents.

Recent Advances / Emerging Therapies

Recent multicenter randomized controlled trials (RCTs), including ESAX-DN and others, have demonstrated that esaxerenone significantly reduces albuminuria and slows CKD progression when added to RAS inhibitors in patients with type 2 diabetes and nephropathy. These benefits are accompanied by modest blood pressure reductions and a lower incidence of hyperkalemia compared to steroidal MRAs. Pharmacodynamic studies further suggest favorable tissue selectivity and reduced risk of gynecomastia or menstrual irregularities. Ongoing trials are evaluating esaxerenone in broader populations, including non-diabetic CKD and heart failure with preserved ejection fraction.

Guideline Recommendations

International guidelines, including those from the Japanese Society of Hypertension and the Kidney Disease: Improving Global Outcomes (KDIGO), now recognize esaxerenone as a valuable add-on therapy in patients with resistant hypertension and diabetic nephropathy not adequately controlled by RAS inhibitors alone. Recommendations emphasize individualized risk assessment, close monitoring for hyperkalemia, and consideration of esaxerenone's pharmacological advantages in patients intolerant to steroidal MRAs. Integration into clinical practice should be guided by patient-specific factors, comorbidity profiles, and shared decision-making.

Conclusion

The addition of esaxerenone to RAS inhibitors represents a paradigm shift in the management of resistant hypertension and proteinuric CKD, offering mechanistic synergy, improved clinical outcomes, and a favorable safety profile. As further evidence accumulates, this therapeutic approach is poised to become an integral component of personalized cardiovascular and renal protection strategies for high-risk patient populations.